(EMAILWIRE.COM, February 19, 2019 ) The global In vitro toxicology testing market was valued at USD 5.99 Billion in 2016 and is expected to grow at a CAGR of 6.6% during the forecast period to reach to USD 8.74 Billion by 2022. The In vitro toxicology testing market includes safety assessment of chemicals, drugs, cosmetic products, food additives, etc, without using animals as test models. This testing is performed on advance cell and tissue models to determine safety by studying the potential of the test substances to cause toxicity, such as genotoxicity, skin irritation and sensitization, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicities. The opposition to animal testing, increasing R&D at early stages of drug development, innovation in cell culture technology are factors driving the growth of the global market.

The report analyzes the global market by products & services, toxicity endpoints and tests, technology, industry, methods, and region.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065

By Toxicity Endpoints and Tests, ADME hold the largest market share in 2017

Based on toxicity endpoints and tests of in vitro toxicology testing, the market is subsegmented into ADME, genotoxicity, skin irritation and sensitization, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicities (eco toxicity, endocrine disruption, and reproductive & developmental toxicity). In 2017, the ADME segment is expected to account for the largest share of the global in vitro toxicology testing market owing to its highly reproducible & accurate data and the increasing demand to curb drug toxicity at the drug development phase.

US expected to hold the largest share of the in vitro toxicology testing market in 2017

US is estimated to account for the largest share among other regions in the in vitro toxicology testing market, followed by Germany and UK. In the Asia Pacific region, China is expected to grow at the highest CAGR during the forecast period.

The major players in the global in vitro toxicology testing market include Cyprotex (An Evotec AG subsidiary, Germany), Covance (A Laboratory Corporations of America Holding’s subsidiary, US), Eurofins Scientific SE (Luxembourg), GE Healthcare (US), Thermo Fisher Scientific (US), SGS SA (Switzerland), Promega Corporation (US), Merck KGaA (Germany), Charles River Laboratories, Inc. (US), and Lonza Group Ltd. (Switzerland), among others.